Moxatag is a drug owned by Pragma Pharmaceuticals Llc. It is protected by 6 US drug patents filed from 2013 to 2015. Out of these, 3 drug patents are active and 3 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 07, 2027. Details of Moxatag's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US8778924 | Modified release amoxicillin products |
Dec, 2026
(a month from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8299052 | Pharmaceutical compositions and methods for improved bacterial eradication |
May, 2027
(6 months from now) | Active |
| US8357394 | Compositions and methods for improved efficacy of penicillin-type antibiotics |
Dec, 2026
(a month from now) | Active |
| US6723341 | Antibiotic product, use and formulation thereof |
Oct, 2020
(6 years ago) |
Expired
|
| US6544555 | Antibiotic product, use and formulation thereof |
Oct, 2020
(6 years ago) |
Expired
|
| US6669948 | Antibiotic product, use and formulation thereof |
Oct, 2020
(6 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Moxatag's patents.
Latest Legal Activities on Moxatag's Patents
Given below is the list of recent legal activities going on the following patents of Moxatag.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Maintenance Fee Reminder Mailed | 02 Mar, 2026 | US8778924 |
| Expire Patent | 24 Feb, 2025 | US8357394 |
| Expire Patent | 02 Dec, 2024 | US8299052 |
| Maintenance Fee Reminder Mailed | 09 Sep, 2024 | US8357394 |
| Maintenance Fee Reminder Mailed
Critical | 17 Jun, 2024 | US8299052 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Jan, 2022 | US8778924 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 Jul, 2020 | US8357394 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Apr, 2020 | US8299052 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Jan, 2018 | US8778924 |
| Mail O.P. Petition Decision | 26 Feb, 2015 | US8299052 |
US patents provide insights into the exclusivity only within the United States, but
Moxatag is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Moxatag's family patents as well as insights into
ongoing legal events
on those patents.
Moxatag's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Moxatag:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
Generic Launch
Generic Release Date:
Moxatag's generic launch date based on the expiry of its last outstanding patent is estimated to be May 07, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Moxatag Generic API suppliers:
Amoxicillin is the generic name for the brand Moxatag. 19 different companies have already filed for the generic of Moxatag, with Apothecon having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Moxatag's generic
Alternative Brands for Moxatag
Moxatag which is used for treating tonsillitis and/or pharyngitis caused by Streptococcus pyogenes with once-a-day amoxicillin product., has several other brand drugs using the same active ingredient (Amoxicillin). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Phathom |
| ||
| Talicia Holdings |
| ||
| Us Antibiotics |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Amoxicillin, Moxatag's active ingredient. Check the complete list of approved generic manufacturers for Moxatag
About Moxatag
Moxatag is a drug owned by Pragma Pharmaceuticals Llc. It is used for treating tonsillitis and/or pharyngitis caused by Streptococcus pyogenes with once-a-day amoxicillin product. Moxatag uses Amoxicillin as an active ingredient. Moxatag was launched by Pragma in 2008.
Approval Date:
Moxatag was approved by FDA for market use on 23 January, 2008.
Active Ingredient:
Moxatag uses Amoxicillin as the active ingredient. Check out other Drugs and Companies using Amoxicillin ingredient
Treatment:
Moxatag is used for treating tonsillitis and/or pharyngitis caused by Streptococcus pyogenes with once-a-day amoxicillin product.
Dosage:
Moxatag is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 775MG | TABLET, EXTENDED RELEASE | Discontinued | ORAL |